Track topics on Twitter Track topics that are important to you
The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half, compared to placebo, regardless of baseline serum urate level.
Original Article: Canakinumab reduces gout rate by more than halfNEXT ARTICLE
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....